Sorafenib (brand name Nexavar) / N-cadherin Cancer Research Results

SRF, Sorafenib (brand name Nexavar): Click to Expand ⟱
Features: kinase inhibitor drug

Sorafenib (brand: Nexavar) — an oral multikinase inhibitor targeting RAF kinases and multiple receptor tyrosine kinases (VEGFR-1/2/3, PDGFR-β, FLT3, KIT, RET). Approved for advanced hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and differentiated thyroid carcinoma (DTC).

Primary mechanisms (conceptual rank):
1) RAF (CRAF/BRAF) inhibition → ↓ MAPK/ERK signaling
2) VEGFR/PDGFR blockade → anti-angiogenesis
3) Induction of mitochondrial apoptosis (Mcl-1↓; caspases↑)
4) Metabolic/redox stress modulation (ROS shifts; ferroptosis sensitization reported)
5) Tumor microenvironment effects (vascular normalization / hypoxia interplay)

Bioavailability / PK relevance: Oral; variable absorption; highly protein-bound; metabolized mainly by CYP3A4 and UGT1A9; half-life ~25–48 h. Achievable plasma levels are within low-micromolar range.

In-vitro vs oral exposure: Many mechanistic studies use concentrations within or slightly above clinical plasma range; off-target cytotoxicity typically at higher doses.

Clinical evidence status: FDA-approved for HCC, RCC, DTC; established survival benefit in advanced disease (modest median OS improvement).

Inhibitors of vascular endothelial growth factor receptor (VEGFR); used to treat kidney, liver and thyroid cancers.

Sorafenib (Nexavar) — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 RAF → MEK → ERK (MAPK) ↓ (primary) ↔ / ↓ (proliferating cells) R/G Reduced proliferative signaling Core intracellular target; inhibits CRAF and wild-type BRAF (not selective for BRAF V600E like vemurafenib).
2 VEGFR / PDGFR (angiogenesis) ↓ tumor vascularization ↓ endothelial proliferation R/G Anti-angiogenic effect Major driver of clinical efficacy in HCC/RCC; affects tumor microenvironment.
3 Intrinsic apoptosis (Mcl-1↓, caspases↑) ↑ ↔ / ↑ (dose-dependent) R/G Mitochondrial apoptosis Mcl-1 downregulation is characteristic; enhances chemosensitivity in some models.
4 ROS ↑ (dose-dependent) ↔ / ↑ (high exposure) P/R Oxidative stress contribution Redox stress may contribute to cytotoxicity and resistance mechanisms.
5 Ferroptosis ↑ (context-dependent) ↔ R/G Lipid peroxidation vulnerability Reported to sensitize HCC cells to ferroptosis via system Xc⁻ / SLC7A11 modulation.
6 PI3K/AKT/mTOR ↓ (secondary; model-dependent) ↔ R/G Reduced survival signaling Often compensatory pathway in resistance; combination target in trials.
7 HIF-1α ↓ (anti-angiogenic coupling) ↔ G Reduced hypoxia signaling Indirect via vascular effects; hypoxia may paradoxically increase in resistant tumors.
8 NRF2 ↑ (resistance-associated; context-dependent) ↔ R/G Adaptive antioxidant response NRF2 upregulation linked to sorafenib resistance in HCC.
9 Ca²⁺ signaling ↔ (stress-related) ↔ P/R Not primary axis Secondary to mitochondrial stress; not direct target.
10 Clinical Translation Constraint ↓ (constraint) ↓ (toxicity) — Resistance + tolerability limits Common AEs: hand-foot skin reaction, hypertension, diarrhea; resistance frequent via MAPK reactivation or NRF2 upshift.

TSF legend:
P: 0–30 min (kinase inhibition onset)
R: 30 min–3 hr (signaling cascade suppression)
G: >3 hr (gene regulation, angiogenesis suppression, apoptosis)
N-cadherin, N-cadherin: Click to Expand ⟱
Source:
Type:
Also known as Cadherin2 (CDH2).
N-cadherin is a type of cell adhesion molecule that plays a crucial role in the development and maintenance of tissue structure. In the context of cancer, N-cadherin has been implicated in the progression and metastasis of various types of tumors.
N-cadherin expression is increased in various types of cancer.
Normally, N-cadherin is expressed in mesenchymal cells, such as fibroblasts and smooth muscle cells. However, in cancer cells, N-cadherin expression is often upregulated, which can contribute to the epithelial-to-mesenchymal transition (EMT). EMT is a process by which epithelial cells acquire a more mesenchymal phenotype, which is characterized by increased motility, invasiveness, and resistance to apoptosis.
The expression of N-cadherin in cancer cells is closely associated with tumorigenesis and metastasis. Additionally, the soluble N-cadherin level in the serum of cancer patients is much higher than that in the serum of healthy patients, revealing a positive relation with poor prognosis.
Scientific Papers found: Click to Expand⟱
6915- FIS,  SRF,    Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma
- in-vitro, Melanoma, NA
EMT↓, TumCP↓, PI3K↓, eff↑, N-cadherin↓, Vim↓, Fibronectin↓, E-cadherin↑, Snail↓, Twist↓, Slug↓, Zeb1↓, MMP2↓, MMP9↓, TumCI↓, TumMeta↓, ChemoSen↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↓, 1,   PI3K↓, 1,  

Migration(tgid=13) ⓘ

E-cadherin↑, 1,   Fibronectin↓, 1,   MMP2↓, 1,   MMP9↓, 1,   N-cadherin↓, 1,   Slug↓, 1,   Snail↓, 1,   TumCI↓, 1,   TumCP↓, 1,   TumMeta↓, 1,   Twist↓, 1,   Vim↓, 1,   Zeb1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   eff↑, 1,  
Total Targets: 17

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: N-cadherin, N-cadherin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:16  Target#:355  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page